Cytek Biosciences downgraded to Sell from Buy at Goldman Sachs
Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...
Adobe says Scott Belsky resigns as Chief Strategy Officer
In a regulatory filing, Adobe (ADBE) disclosed that on January 24, Scott Belsky notified the company of his decision to resign as Chief ...
Watch live: Defense secretary addresses nation as 67 passengers feared dead after American Airlines jet collides with military helicopter
Defense secretary addresses nation as 67 passengers feared dead after American Airlines jet collides with military helicopter - ...
Here’s Why Tsai Capital Added QXO (QXO) to its Portfolio?
Tsai Capital, an investment management company, released its fourth quarter investor letter. A copy of the letter can be ...
Insights Into Microsoft's Performance Versus Peers In Software Sector
When considering the debt-to-equity ratio, Microsoft exhibits a stronger financial position compared to its top 4 peers. This indicates that the company has a favorable balance between debt and equity ...
Calix stock holds Buy rating and $45 target from Needham
Calix (NYSE:CALX) shares maintained their Buy rating and $45.00 price target from Needham, following the company's fourth-quarter earnings results. Needham analysts highlighted Calix's revenue and non ...